

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journal Browser
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Detection of micrometastasis through tissue-specific gene expression: its promise and problems.

Jung R, Soondrum K, Kruger W, Neumaier M.

Department of Clinical Chemistry, University Clinic Hamburg-Eppendorf, Germany.

The detection of micrometastasis holds great promise for earlier staging of patients with malignant diseases and may ultimately guide therapeutic decisions. So far, reverse-transcriptase polymerase chain reaction (RT-PCR) amplification of genes expressed by the tumor in a tissue-specific manner is the method with the highest diagnostic sensitivity. It is well-established that the identification of single tumor cells is feasible in tissues and bodily fluids in both experimental and clinical samples. However, at present it is difficult to assign clinical significance to results obtained from such tests, primarily because their diagnostic specificity is disputed, both conceptionally and methodologically. For example, amplification of candidate mRNA targets is detectable in non-cancer patients using conditions that generally fail to generate such signals from healthy individuals. We have established that transcription of the tissue-specific genes can be affected by different means. Specifically, some target mRNA species are detectable in peripheral blood nuclear cells as low abundance constitutive-like expression, whereas others are induced through in vitro tissue culturing. In addition, mRNA expression may be distinctly upregulated by different cytokines or growth factors in vivo. Also, background transcription of target mRNAs can occur in different lineages of peripheral blood cells. Finally, expression may be substantially different in tissues such as peripheral blood, bone marrow, or lymph nodes. As a consequence, cancer patients in unrelated clinical situations may present with different levels of background expression, making the diagnostic specificity of test results difficult to assess. To add to this complexity, an increasing body of literature is being generated using various targets for a multitude of malignant diseases. There is a great variety of methods for sampling, specimen processing, nucleic acids recovery, test conditions, and readout formats, making it impossible to compare data. In summary, modalities of quantitative RT-PCR methods and standardization issues should be discussed to address these questions.

```
(Item 2 from file: 5)
2/3/2
DIALOG(R) File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
          BIOSIS NO.: 200100119022
12911873
Isolation of a novel human lung-specific gene, LUNX, a potential
molecular marker for detection of micrometastasis in non-small-cell
                                                                       luna
   cancer.
AUTHOR: Iwao Kyoko; Watanabe Takashi; Fujiwara Yoshiyuki(a); Takami Koji;
  Kodama Ken; Higashiyama Masahiko; Yokouchi Hideki; Ozaki Kouichi; Monden
 Morito; Tanigami Akira
AUTHOR ADDRESS: (a) Department of Surgery and Clinical Oncology, Graduate
  School of Medicine, Osaka University, 2-2 Yamada-Oka, Suita City, Osaka,
  565-0871: fujiwara@surg2.med.osaka-u.ac.jp**Japan
JOURNAL: International Journal of Cancer 91 (4):p433-437 February 15, 2001
MEDIUM: print
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English
        (Item 3 from file: 5)
2/3/3
DIALOG(R) File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
12516792
          BIOSIS NO.: 200000270294
Isolation of a novel human lung-specific gene, LUNX, a potential
 molecular marker for detection of micrometastasis in non-small cell
AUTHOR: Fujiwara Yoshiyuki(a); Iwao Kyoko; Tanigami Akira; Takami Koji;
  Monden Morito; Shiozaki Hitoshi; Yano Masahiko; Inoue Masatomo; Doki
  Yuuichiro
AUTHOR ADDRESS: (a)Osaka Med Ctr for Cancer and CV Diseases, Saka**Japan
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting (41):p691 March, 2000
MEDIUM: print.
CONFERENCE/MEETING: 91st Annual Meeting of the American Association for
Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English
 2/3/4
          (Item 4 from file: 5)
              5:Biosis Previews(R)
DIALOG(R)File
(c) 2001 BIOSIS. All rts. reserv.
11624203
           BIOSIS NO.: 199800406449
Isolation and characterization of a novel human lung- specific
 homologous to lysosomal membrane glycoproteins 1 and 2: Significantly
increased expression in cancers of various tissues.

AUTHOR: Ozaki Kouichi(a); Nagata Masami; Suzuki Mikio; Fujiwara Tsutomu;
  Ueda Kazuki; Miyoshi Yasuo; Takahashi Ei-Ichi; Nakamura Yusuke
AUTHOR ADDRESS: (a) Otsuka GEN Res. Inst., Otsuka Pharm. Co. Ltd., 463-10
  Kagasuno Kawauchi-cho, Tokushima 771-0192**Japan
JOURNAL: Cancer Research 58 (16):p3499-3503 Aug. 15, 1998
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
          (Item 1 from file: 34)
 2/3/5
DIALOG(R) File 34: SciSearch(R) Cited Ref Sci
(c) 2001 Inst for Sci Info. All rts. reserv.
                                    No. References: 27
          Genuine Article#: 255HH
08183093
Title: Isolation and mapping of a human lung- specific
                                                           gene, TSA1902,
   encoding a novel chitinase family member
Author(s): Saito A; Ozaki K; Fujiwara T; Nakamura Y; Tanigami A (REPRINT)
```

Corporate Source: OTSUKA PHARMACEUT CO LTD, OTSUKA GEN RES INST, 463-10

KAGASUNO/KAWAUCHI/TOKUSHIMA 7710192/JAPAN/ (REPRINT); OTSUKA PHARMACEUT CO LTD, OTSUKA GEN RES INST/KAWAUCHI/TOKUSHIMA 7710192/JAPAN/; UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MOL MED LAB/TOKYO 1080071//JAPAN/ Journal: GENE, 1999, V239, N2 (NOV 1), P325-331 ISSN: 0378-1119 Publication date: 19991101 Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE) 2/3/7 (Item 1 from file: 357) DIALOG(R)File 357:Derwent Biotechnology Abs (c) 2001 Derwent Publ Ltd. All rts. reserv. 0251526 DBA Accession No.: 2000-06016 PATENT Lung specific genes for developing products for diagnosing, monitoring, staging, prognosticating, imaging and treating lung cancer - lung- specific- gene specific antibody, used to detect lung specific gene expression in non-lung tissue, used to detect and treat lung cancer metastasis AUTHOR: Yang F; Sun Y; Recipon H; Macina R A CORPORATE SOURCE: Santa Clara, CA, USA. PATENT ASSIGNEE: Diadexus 2000 PATENT NUMBER: WO 200008206 PATENT DATE: 20000217 WPI ACCESSION NO.: 2000-195589 (2017) PRIORITY APPLIC. NO.: US 95233 APPLIC. DATE: 19980804 NATIONAL APPLIC. NO.: WO 99US16247 APPLIC. DATE: 19990719 LANGUAGE: English 2/3/8 (Item 2 from file: 357) DIALOG(R) File 357: Derwent Biotechnology Abs (c) 2001 Derwent Publ Ltd. All rts. reserv. 0249851 DBA Accession No.: 2000-04341 A new method for diagnosis, monitoring, and staging lung cancer involving determining the level of lung specific gene AUTHOR: Yang F; Macina R A; Sun Y CORPORATE SOURCE: Santa Clara, CA, USA. PATENT ASSIGNEE: Diadexus 1999 PATENT NUMBER: WO 9960160 PATENT DATE: 19991125 WPI ACCESSION NO.: 2000-116320 (2010) PRIORITY APPLIC. NO.: US 86212 APPLIC. DATE: 19980521 NATIONAL APPLIC. NO.: WO 99US10344 APPLIC. DATE: 19990512 LANGUAGE: English

```
(Item 2 from file: 5)
DIALOG(R)File
              5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
          BIOSIS NO.: 200100119022
Isolation of a novel human lung-specific gene, LUNX, a potential
 molecular marker for detection of micrometastasis in non-small-cell
    cancer.
AUTHOR: Iwao Kyoko; Watanabe Takashi; Fujiwara Yoshiyuki(a); Takami Koji;
  Kodama Ken; Higashiyama Masahiko; Yokouchi Hideki; Ozaki Kouichi; Monden
  Morito: Tanigami Akira
AUTHOR ADDRESS: (a) Department of Surgery and Clinical Oncology, Graduate
  School of Medicine, Osaka University, 2-2 Yamada-Oka, Suita City, Osaka,
  565-0871: fujiwara@surq2.med.osaka-u.ac.jp**Japan
JOURNAL: International Journal of Cancer 91 (4):p433-437 February 15, 2001
MEDIUM: print
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English
         (Item 3 from file: 5)
2/3/3
DIALOG(R) File
              5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
12516792 BIOSIS NO.: 200000270294
Isolation of a novel human lung-specific gene, LUNX, a potential
 molecular marker for detection of micrometastasis in non-small cell lung
AUTHOR: Fujiwara Yoshiyuki(a); Iwao Kyoko; Tanigami Akira; Takami Koji;
  Monden Morito; Shiozaki Hitoshi; Yano Masahiko; Inoue Masatomo; Doki
  Yuuichiro
AUTHOR ADDRESS: (a) Osaka Med Ctr for Cancer and CV Diseases, Saka**Japan
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting (41):p691 March, 2000
MEDIUM: print.
CONFERENCE/MEETING: 91st Annual Meeting of the American Association for
Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English
 2/3/4
         (Item 4 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
          BIOSIS NO.: 199800406449
11624203
Isolation and characterization of a novel human lung-specific
homologous to lysosomal membrane glycoproteins 1 and 2: Significantly
 increased expression in cancers of various tissues.
AUTHOR: Ozaki Kouichi(a); Nagata Masami; Suzuki Mikio; Fujiwara Tsutomu;
  Ueda Kazuki; Miyoshi Yasuo; Takahashi Ei-Ichi; Nakamura Yusuke
AUTHOR ADDRESS: (a) Otsuka GEN Res. Inst., Otsuka Pharm. Co. Ltd., 463-10
  Kagasuno Kawauchi-cho, Tokushima 771-0192**Japan
JOURNAL: Cancer Research 58 (16):p3499-3503 Aug. 15, 1998
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
          (Item 1 from file: 34)
2/3/5
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci
(c) 2001 Inst for Sci Info. All rts. reserv.
          Genuine Article#: 255HH
                                   No. References: 27
Title: Isolation and mapping of a human lung- specific
                                                        gene, TSA1902,
   encoding a novel chitinase family member
Author(s): Saito A; Ozaki K; Fujiwara T; Nakamura Y; Tanigami A (REPRINT)
```

Corporate Source: OTSUKA PHARMACEUT CO LTD, OTSUKA GEN RES INST, 463-10

KAGASUNO/KAWAUCHI/TOKUSHIMA 7710192/JAPAN/ (REPRINT); OTSUKA PHARMACEUT CO LTD, OTSUKA GEN RES INST/KAWAUCHI/TOKUSHIMA 7710192/JAPAN/; UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MOL MED LAB/TOKYO 1080071//JAPAN/ Journal: GENE, 1999, V239, N2 (NOV 1), P325-331 ISSN: 0378-1119 Publication date: 19991101 Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE) (Item 1 from file: 357) 2/3/7 DIALOG(R) File 357: Derwent Biotechnology Abs (c) 2001 Derwent Publ Ltd. All rts. reserv. 0251526 DBA Accession No.: 2000-06016 PATENT Lunq specific genes for developing products for diagnosing, monitoring, staging, prognosticating, imaging and treating lung cancer - lung- specific- gene specific antibody, used to detect lung specific gene expression in non-lung tissue, used to detect and treat lung cancer metastasis AUTHOR: Yang F; Sun Y; Recipon H; Macina R A CORPORATE SOURCE: Santa Clara, CA, USA. PATENT ASSIGNEE: Diadexus 2000 PATENT NUMBER: WO 200008206 PATENT DATE: 20000217 WPI ACCESSION NO.: 2000-195589 (2017) PRIORITY APPLIC. NO.: US 95233 APPLIC. DATE: 19980804 NATIONAL APPLIC. NO.: WO 99US16247 APPLIC. DATE: 19990719 LANGUAGE: English (Item 2 from file: 357) 2/3/8 DIALOG(R) File 357: Derwent Biotechnology Abs (c) 2001 Derwent Publ Ltd. All rts. reserv. 0249851 DBA Accession No.: 2000-04341 A new method for diagnosis, monitoring, and staging lung cancer involving determining the level of lung specific gene AUTHOR: Yang F; Macina R A; Sun Y CORPORATE SOURCE: Santa Clara, CA, USA. PATENT ASSIGNEE: Diadexus 1999 PATENT NUMBER: WO 9960160 PATENT DATE: 19991125 WPI ACCESSION NO.: 2000-116320 (2010) PRIORITY APPLIC. NO.: US 86212 APPLIC. DATE: 19980521 NATIONAL APPLIC. NO.: WO 99US10344 APPLIC. DATE: 19990512 LANGUAGE: English 2/9/1 (Item 1 from file: 5) DIALOG(R) File 5: Biosis Previews (R) (c) 2001 BIOSIS. All rts. reserv. 12911873 BIOSIS NO.: 200100119022 Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung AUTHOR: Iwao Kyoko; Watanabe Takashi; Fujiwara Yoshiyuki(a); Takami Koji; Kodama Ken; Higashiyama Masahiko; Yokouchi Hideki; Ozaki Kouichi; Monden Morito; Tanigami Akira AUTHOR ADDRESS: (a) Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2-2 Yamada-Oka, Suita City, Osaka, 565-0871: fujiwara@surq2.med.osaka-u.ac.jp**Japan JOURNAL: International Journal of Cancer 91 (4):p433-437 February 15, 2001 MEDIUM: print ISSN: 0020-7136 DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English SUMMARY LANGUAGE: English ABSTRACT: We have isolated a novel human lung -specific gene , LUNX (lung-specific X protein), by differential-display mRNA analysis. The full-length cDNA contained 1,015 nucleotides including an open reading

frame of 768 nucleotides encoding 256 amino acids. We localized the gene to chromosomal region 20p11.1-q12 by radiation hybrid mapping. Using an

RT-PCR assay specific for LUNX mRNA, 35 non-small-cell lung -cancer (NSCLC) tumors and 0 of 16 normal lymph nodes were positive. Furthermore, LUNX mRNA expression was enhanced in 26 (84%) of 31 NSCLC tumors vs. corresponding cancer -free lung tissues by semi-quantitative analyses with multiplex RT-PCR. We assessed the possibility of LUNX mRNA as a molecular marker for detection of micrometastasis in dissected lymph nodes obtained from 20 patients with NSCLC tumors. LUNX mRNA was detected in 16 (80%) of 20 histologically positive lymph nodes and 21 (25%) of 84 histologically negative lymph nodes. Comparative analyses of the conventional histological examination and the RT-PCR detection assay for LUNX mRNA showed that the detection rate of metastases in lymph nodes by the RT-PCR assay was higher in 12 and consistent in 6 of the total 20 NSCLC patients. We demonstrate that the LUNX RT-PCR assay is a potential diagnostic method for detection of micrometastases in lymph nodes of NSCLC patients.

```
diagnostic method for detection of micrometastases in lymph nodes of
  NSCLC patients.
DESCRIPTORS:
  MAJOR CONCEPTS: Clinical Chemistry (Allied Medical Sciences); Medical
    Genetics (Allied Medical Sciences); Oncology (Human Medicine, Medical
    Sciences); Pulmonary Medicine (Human Medicine, Medical Sciences)
  BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
    Animalia
  ORGANISMS: human (Hominidae) -- patient
  ORGANISMS: PARTS ETC: chromosome 20--location pl1.1, location q12
  BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans;
    Mammals; Primates; Vertebrates
  DISEASES: non-small cell lung cancer --neoplastic disease, respiratory
    system disease
  GENE NAME: human LUNX gene (Hominidae) -- isolation, lung -specific
  METHODS & EQUIPMENT: RT-PCR {reverse transcriptase-polymerase chain
    reaction}--gene amplification method; radiation hybrid mapping--
    analytical method
ALTERNATE INDEXING: Lung Neoplasms (MeSH); Carcinoma, Non-Small-Cell
    Lung (MeSH
CONCEPT CODES:
  16006
         Respiratory System-Pathology
         Genetics and Cytogenetics-Human
  03508
         Clinical Biochemistry; General Methods and Applications
  10006
          Biochemical Studies-Nucleic Acids, Purines and Pyrimidines
  10062
  24004
          Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects;
             Systemic Effects
           (Item 2 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
          BIOSIS NO.: 200000270294
Isolation of a novel human lung-specific gene, LUNX, a potential
 molecular marker for detection of micrometastasis in non-small cell
AUTHOR: Fujiwara Yoshiyuki(a); Iwao Kyoko; Tanigami Akira; Takami Koji;
 Monden Morito; Shiozaki Hitoshi; Yano Masahiko; Inoue Masatomo; Doki
  Yuuichiro
AUTHOR ADDRESS: (a) Osaka Med Ctr for Cancer and CV Diseases, Saka**Japan
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting (41):p691 March, 2000
MEDIUM: print.
CONFERENCE/MEETING: 91st Annual Meeting of the American Association for
Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English
DESCRIPTORS:
 MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular
    Biophysics); Oncology (Human Medicine, Medical Sciences)
 BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
```

Animalia

```
ORGANISMS: human (Hominidae) -- patient
  BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans;
    Mammals; Primates; Vertebrates
                                 cancer --lymph node micrometastasis
  DISEASES: non-small cell lung
    detection, neoplastic disease, respiratory system disease
  CHEMICALS & BIOCHEMICALS: lung-specific X protein gene {LUNX gene}
    (Hominidae) -- isolation, potential molecular diagnostic marker
  MISCELLANEOUS TERMS: Meeting Abstract
ALTERNATE INDEXING: Lung Neoplasms (MeSH); Carcinoma, Non-Small-Cell
    Lung (MeSH
CONCEPT CODES:
         Genetics and Cytogenetics-Human
  03508
          Pathology, General and Miscellaneous-Diagnostic
  12504
  16006
          Respiratory System-Pathology
         Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects;
  24004
             Systemic Effects
  24001
          Neoplasms and Neoplastic Agents-Diagnostic Methods
         General Biology-Symposia, Transactions and Proceedings of
  00520
            Conferences, Congresses, Review Annuals
BIOSYSTEMATIC CODES:
  86215 Hominidae
 2/9/3
         (Item 3 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
         BIOSIS NO.: 199800406449
11624203
Isolation and characterization of a novel human lung-specific
homologous to lysosomal membrane glycoproteins 1 and 2: Significantly
 increased expression in cancers of various tissues.
AUTHOR: Ozaki Kouichi(a); Nagata Masami; Suzuki Mikio; Fujiwara Tsutomu;
  Ueda Kazuki; Miyoshi Yasuo; Takahashi Ei-Ichi; Nakamura Yusuke
AUTHOR ADDRESS: (a)Otsuka GEN Res. Inst., Otsuka Pharm. Co. Ltd., 463-10
  Kagasuno Kawauchi-cho, Tokushima 771-0192**Japan
JOURNAL: Cancer Research 58 (16):p3499-3503 Aug. 15, 1998
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
ABSTRACT: We have isolated and characterized a novel human lung -specific
  gene and observed its increased expression in cancers arising from
  various tissues. The cDNA, designated TSC403, contained an open reading
  frame of 1248 nucleotides encoding 416 amino acids; the deduced amino
  acid sequence showed significant similarities to lysosomal membrane
  glycoproteins (lamps) 1 and 2. We localized the gene to chromosomal band
  3q27, a genomic region that is often amplified in human cancers of
  several tissue types. We detected a high level of the TSC403 transcript
  in primary cancers of the esophagus, colon, fallopian tube, ovary,
  breast, and liver, although expression of this gene was barely detectable
  in corresponding normal tissues. These findings indicated that
 up-regulation of the TSC403 transcript may be related to the development
  and/or progression of cancer in humans.
DESCRIPTORS:
 MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular
   Biophysics); Tumor Biology
  BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
   Animalia
  ORGANISMS: human (Hominidae) -- patient
  BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans;
   Mammals; Primates; Vertebrates
  DISEASES: breast cancer --neoplastic disease, reproductive system
   disease/female, tumor progression, tumor development; colon cancer --
   digestive system disease, tumor progression, tumor development,
   neoplastic disease; esophageal cancer --digestive system disease,
   tumor progression, tumor development, neoplastic disease; fallopian
   tube cancer -- neoplastic disease, tumor progression, tumor development
```

, reproductive system disease/female; liver cancer --digestive system

```
disease, tumor development, tumor progression, neoplastic disease;
    ovarian cancer --endocrine disease/gonads, tumor development,
    reproductive system disease/female, tumor progression, neoplastic
    disease
  CHEMICALS & BIOCHEMICALS:
                              TSC-403 lung -specific
                                                       gene --amino acid
    sequence, chromosome band 3q27 localization, lysosomal membrane
    glycoprotein 2 homology, lysosomal membrane glycoprotein 1 homology,
    tumor expression, nucleotide sequence
CONCEPT CODES:
          Neoplasms and Neoplastic Agents-Carcinogens and Carcinogenesis
  24007
  03508
          Genetics and Cytogenetics-Human
  10508
          Biophysics-Membrane Phenomena
  13004
          Metabolism-Carbohydrates
          Metabolism-Proteins, Peptides and Amino Acids
  13012
  14006
          Digestive System-Pathology
  16506
          Reproductive System-Pathology
  17006
          Endocrine System-Gonads and Placenta
  24006
          Neoplasms and Neoplastic Agents-Biochemistry
  02508
          Cytology and Cytochemistry-Human
          Biochemical Studies-Nucleic Acids, Purines and Pyrimidines
  10062
  10064
          Biochemical Studies-Proteins, Peptides and Amino Acids
  10068
          Biochemical Studies-Carbohydrates
  10506
          Biophysics-Molecular Properties and Macromolecules
BIOSYSTEMATIC CODES:
  86215 Hominidae
          (Item 1 from file: 34)
 2/9/4
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2001 Inst for Sci Info. All rts. reserv.
           Genuine Article#: 255HH Number of References: 27
08183093
Title: Isolation and mapping of a human lung- specific gene, TSA1902,
   encoding a novel chitinase family member
Author(s): Saito A; Ozaki K; Fujiwara T; Nakamura Y; Tanigami A (REPRINT)
Corporate Source: OTSUKA PHARMACEUT CO LTD, OTSUKA GEN RES INST, 463-10
    KAGASUNO/KAWAUCHI/TOKUSHIMA 7710192/JAPAN/ (REPRINT); OTSUKA PHARMACEUT
    CO LTD, OTSUKA GEN RES INST/KAWAUCHI/TOKUSHIMA 7710192/JAPAN/; UNIV
    TOKYO, INST MED SCI, CTR HUMAN GENOME, MOL MED LAB/TOKYO 1080071//JAPAN/
Journal: GENE, 1999, V239, N2 (NOV 1), P325-331
ISSN: 0378-1119
                 Publication date: 19991101
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
Language: English
                   Document Type: ARTICLE
Geographic Location: JAPAN
Subfile: CC LIFE--Current Contents, Life Sciences
Journal Subject Category: GENETICS & HEREDITY
Abstract: Using differential display technique, we have isolated a novel
    human gene expressed specifically in the lung. Two forms of the gene,
    designated TSA1902, were transcribed by alternate mRNA splicing. The
    transcribed mRNAs, termed TSA1902-L and TSA1902-S, putatively encode
    proteins of 368 and 315 amino acids, respectively, which show high
    similarity to human chitotriosidase protein. The N-terminal region of
    TSA1902-L protein contains the conserved active site residues
    (DXXDXDXE) of the catalytic center of various chitinases which are
    essential for chitinase activity. The deduced protein sequence of
    TSA1902-S, however, does not possess this active site, with the
    N-terminal 54 amino acids present in TSA1902-L protein having been
    deleted. Both proteins lacked the secretory sequence of N-termini and,
    judging from the hydropathy profile, may be soluble proteins in the
    cytoplasm. Chromosomal mapping by radiation hybrid analysis localized
    this gene to the chromosome 1pl3.1-p21.3. (C) 1999 Elsevier Science
    B.V. All rights reserved.
Descriptors--Author Keywords: chitinase ; lung -specific
                                                           gene ;
    differential display
Identifiers--KeyWord Plus(R): BACILLUS-CIRCULANS WL-12; MOLECULAR-CLONING;
    PROTEIN FAMILY; MESSENGER-RNA; CHITOTRIOSIDASE; GLYCOPROTEIN;
    MACROPHAGES; RESIDUES; DISPLAY; CANCER
Cited References:
    ALTSCHUL SF, 1990, V215, P403, J MOL BIOL
    ARIAS EB, 1994, V51, P685, BIOL REPROD
```

```
BOOT RG, 1995, V270, P26252, J BIOL CHEM
    BOOT RG, 1998, V273, P25680, J BIOL CHEM
    FLACH J, 1992, V48, P701, EXPERIENTIA
    GASPARIAN AV, 1998, V77, P1604, BRIT J CANCER
    HAKALA BE, 1993, V268, P25803, J BIOL CHEM
    HIROKAWA T, 1998, V14, P378, BIOINFORMATICS
    HOLLAK CEM, 1994, V93, P1288, J CLIN INVEST
    HU B, 1996, V271, P19415, J BIOL CHEM
    JOHANSSON M, 1994, V57, P463, INT J CANCER
    KURANDA MJ, 1991, V266, P19758, J BIOL CHEM
    KYTE J, 1982, V157, P105, J MOL BIOL
    LIANG P, 1992, V257, P967, SCIENCE
    MORRISON BW, 1994, V9, P3417, ONCOGENE
    MUZZARELLI RAA, 1986, CHITIN
    OZAKI K, 1998, V58, P3499, CANCER RES
    OZAKI K, 1998, V22, P179, GENE CHROMOSOME CANC
    OZAKI K, 1996, V36, P316, GENOMICS
    RENKEMA GH, 1998, V251, P504, EUR J BIOCHEM
    ROBERTS WK, 1988, V134, P169, J GEN MICROBIOL
    SCHLUMBAUM A, 1986, V324, P365, NATURE
    SENDAI Y, 1995, V53, P285, BIOL REPROD
    SHEN ZC, 1997, V272, P28895, J BIOL CHEM
    TAKAYA N, 1998, V144, P2647, MICROBIOL-UK
    WATANABE T, 1994, V58, P2283, BIOSCI BIOTECH BIOCH
    WATANABE T, 1993, V268, P18567, J BIOL CHEM
           (Item 1 from file: 65)
DIALOG(R) File 65: Inside Conferences
(c) 2001 BLDSC all rts. reserv. All rts. reserv.
          INSIDE CONFERENCE ITEM ID: CN028054696
Isolation and characterization of a novel human lung- specific
                                                                   gene
homologous to lysosomal membrane glycoproteins 1 and 2 -Increased
expression in various cancers
  Ozaki, K.; Suzuki, M.; Fujiwara, T.; Ueda, K.
  CONFERENCE: Cancer genetics &tumor suppressor genes-Meeting
  ABSTRACTS OF PAPERS PRESENTED AT THE MEETING ON CANCER GENETICS AND
  TUMOR SUPPRESSOR GENES, 1998 P: 176
  Cold Spring Harbor Laboratory, 1998
  LANGUAGE: English DOCUMENT TYPE: Conference Abstracts and programme
    CONFERENCE SPONSOR: Cold Spring Harbor Laboratory
    CONFERENCE LOCATION: Cold Spring Harbor, NY
    CONFERENCE DATE: Aug 1998 (199808) (199808)
  BRITISH LIBRARY ITEM LOCATION: 0566.578592
  DESCRIPTORS: cancer genetics; tumor suppressor genes; CSH
          (Item 1 from file: 357)
DIALOG(R) File 357: Derwent Biotechnology Abs
(c) 2001 Derwent Publ Ltd. All rts. reserv.
0251526 DBA Accession No.: 2000-06016
                                         PATENT
Lung specific genes for developing products for diagnosing, monitoring,
   staging, prognosticating, imaging and treating lung cancer - lung
   - specific- gene specific antibody, used to detect lung
                                                             specific
    gene expression in non-lung tissue, used to detect and treat lung
    cancer
            metastasis
AUTHOR: Yang F; Sun Y; Recipon H; Macina R A
CORPORATE SOURCE: Santa Clara, CA, USA.
PATENT ASSIGNEE: Diadexus 2000
PATENT NUMBER: WO 200008206 PATENT DATE: 20000217 WPI ACCESSION NO.:
    2000-195589 (2017)
PRIORITY APPLIC. NO.: US 95233 APPLIC. DATE: 19980804
NATIONAL APPLIC. NO.: WO 99US16247 APPLIC. DATE: 19990719
LANGUAGE: English
ABSTRACT: A means of diagnosing lung cancer, involving measuring the
    expression of lung specific genes in cells, tissues or bodily fluids,
    is claimed. Levels are then compared with levels in normal tissues.
```

Also claimed is a means of staging or monitoring changes in lung

cancer in a patient, an antibody specific to a lung specific gene with a given 1,016 or 597 bp DNA sequence, and a means of imaging a lung cancer in a patient using that antibody. These are used for diagnosis, monitoring, staging and prognosing lung cancer, especially lung cancer metastasis . The antibodies can be linked to a cytotoxic agent and used in lung cancer metastasis therapy. It is particularly used to detect new metastasis of lung cancer by periodically determining the level of lung specific gene expression in cells, tissues or bodily fluids. Positive results are characterized by lung specific gene expression at at least 2 times, preferably five times higher than in normal non-lung tissue. The given DNA sequences correspond to Lng109 (597 bp) and Lng110 (1,016 bp). Lng109 has a relative expression of 46.6 in lungs, with only testis (12.1) and brain (26.6) showing considerable levels expression. (37pp) DESCRIPTORS: lung -specific gene specific antibody, gene expression detection, polymerase chain reaction, in situ hybridization, appl. lung metastasis, cancer diagnosis, imaging, monitoring, prognosis, pot. therapy DNA sequence tumor DNA amplification(Vol.19, No.11) SECTION: PHARMACEUTICALS-Antibodies; PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (D6, D7, A1) (Item 2 from file: 357) DIALOG(R) File 357: Derwent Biotechnology Abs (c) 2001 Derwent Publ Ltd. All rts. reserv. PATENT 0249851 DBA Accession No.: 2000-04341 A new method for diagnosis, monitoring, and staging lung cancer involving determining the level of lung specific gene AUTHOR: Yang F; Macina R A; Sun Y CORPORATE SOURCE: Santa Clara, CA, USA. PATENT ASSIGNEE: Diadexus 1999 PATENT NUMBER: WO 9960160 PATENT DATE: 19991125 WPI ACCESSION NO.: 2000-116320 (2010) PRIORITY APPLIC. NO.: US 86212 APPLIC. DATE: 19980521 NATIONAL APPLIC. NO.: WO 99US10344 APPLIC. DATE: 19990512 LANGUAGE: English ABSTRACT: Diagnosis of lung cancer in a patient involves measuring Lung specific gene (LSG) levels in a cell, tissue or body fluid sample of the patient and a control, whereby increased LSC lovels in the patient compared to the control are associated with the presence of cancer . Also claimed are: diagnosis of lung cancer metastasis in a patient involving measuring LSG levels; staging lung cancer in a patient involving identifying a patient with lung cancer , involving measuring LSG levels in a cell, tissue or body fluid and comparing levels with those of a control; monitoring lung cancer in a patient for the onset of metastasis ; and monitoring changes in a state of lung cancer in a patient, involving identifying a patient as having lung cancer , periodically measuring LSG levels in a cell, tissue or body fluid sample, and comparing levels with a sample from a control. The method can give a prognosis of lung cancer . The method is more accurate than prior art clinical methods for staging lung cancer and unlike pathological staging methods does not depend upon invasive procedure. (24pp) DESCRIPTORS: lung cancer diagnosis, staging, monitoring, prognosis, specific gene level det. in cell, tissue, body fluid tumor (Vol.19, No.8) SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (D7, A1) 0242517 DBA Accession No.: 1999-13282 PATENT Human lung-specific gene TSC430 overexpressed in cancer tissue, used for the treatment of e.g. colon cancer - TSC430 lung and cancer cell-associated protein and ING1L, a tumor suppressor, useful in the diagnosis and therapy of a range of cancer types AUTHOR: Nagata M; Ozaki K; Shimada Y; Horie M CORPORATE SOURCE: Tokyo, Japan. PATENT ASSIGNEE: Otsuka-Pharm. 1999 PATENT NUMBER: WO 9940190 PATENT DATE: 19990812 WPI ACCESSION NO.:

```
1999-494294 (1941)
PRIORITY APPLIC. NO.: JP 98134679 APPLIC. DATE: 19980428
NATIONAL APPLIC. NO.: WO 99JP419 APPLIC. DATE: 19990202
LANGUAGE: Japanese
ABSTRACT: A human TSC403 gene (I) expressed in normal lung tissues and in
     various cancer cell cultures, and a second gene, a human tumor
    suppressor gene ING1L (II) involved in regulation of the cell cycle and
    also cell proliferation, are claimed. Also new are: variants and
    antisense sequences of (I) and (II); (I) and (II)-derived DNA probes
    and DNA primers useful for diagnosing cancer; kits comprising the DNA
    probes and DNA primers; proteins produced from the expression of (I)
    and (II); and antibodies specific for these proteins. (I) is useful for
     the diagnosis and therapy of e.g. lung cancer, mamma cancer, fallopian tube cancer, oesophagus cancer, colon cancer, parotid
     gland cancer , thyroid cancer , bladder cancer , ovary cancer or
     pancreas cancer . (II) is useful for the diagnosis and therapy of
     colon cancer , stomach cancer , oesophagus cancer and fallopian
    tube cancer , and also for studying cell aging, and clarifying disease
    pathology. Both (I) and (II) are also useful in drug screening. (99pp)
DESCRIPTORS: human lung , cancer cell-associated TSC403 prep., ING1L
    tumor suppressor prep., DNA probe, DNA primer, antisense, appl. e.g.
    ovary cancer , fallopian tube cancer , lung cancer , pancreas
   cancer , oesophagus cancer , colon cancer diagnosis, therapy, drug
    screening mammal animal DNA sequence protein sequence hybridization
    DNA amplification tumor (Vol.18, No.23)
SECTION: PHARMACEUTICALS-Peptides and Proteins; PHARMACEUTICALS-Clinical
    Genetic Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid
    Technology (D3, D7, A1)
           (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
             CA: 134(18)247987q
                                    PATENT
 Human lung-specific gene, LUNX, a potential molecular marker for
detection of micrometastasis in non-small-cell lung cancer
  INVENTOR(AUTHOR): Monden, Morito; Fujiwara, Yoshiyuki; Watanabe, Takashi;
Ozaki, Koichi
  LOCATION: Japan,
  ASSIGNEE: Ohtsuka Pharmaceutical Co., Ltd.
  PATENT: Japan Kokai Tokkyo Koho; JP 200178772 A2 DATE: 20010327
  APPLICATION: JP 99253186 (19990907)
  PAGES: 30 pp. CODEN: JKXXAF LANGUAGE: Japanese CLASS: C12N-015/09A;
C07K-014/82B; C07K-016/32B; C12N-001/15B; C12N-001/19B; C12N-001/21B;
C12N-005/10B; C12Q-001/68B; G01N-033/15B; G01N-033/50B; G01N-033/566B;
G01N-033/574B; A61K-031/713B; A61K-035/12B; A61K-035/76B; A61K-039/395B;
A61K-048/00B; A61P-035/00B; A61P-035/04B; C12P-021/08B
  SECTION:
CA203003 Biochemical Genetics
CA206XXX General Biochemistry
CA214XXX Mammalian Pathological Biochemistry
  IDENTIFIERS: human lung gene LUNX marker micrometastasis nonsmall cell
cancer, gene LUNX cDNA sequence human
  DESCRIPTORS:
Diagnosis...
    cancer; human lung-specific gene, LUNX, a potential mol. marker to:
    detection of micrometastasis in non-small-cell lung cancer
Intestine, neoplasm...
    colorectal, LUNX expression in; human lung-specific gene, LUNX, a
    potential mol. marker for detection of micrometastasis in
    non-small-cell lung cancer
Antibodies... cDNA sequences... Genetic mapping... Genetic markers...
Gene, animal... Molecular cloning... Probes (nucleic acid)... Protein
sequences... Test kits...
    human lung-specific gene, LUNX, a potential mol. marker for detection
    of micrometastasis in non-small-cell lung cancer
   human 20; human lung-specific gene, LUNX, a potential mol. marker for
```

detection of micrometastasis in non-small-cell lung cancer

```
LUNX (lung-specific X protein); human lung-specific gene, LUNX, a
    potential mol. marker for detection of micrometastasis in
    non-small-cell lung cancer
Liver, neoplasm...
    LUNX expression in; human lung-specific gene, LUNX, a potential mol.
    marker for detection of micrometastasis in non-small-cell lung cancer
Esophagus... Mammary gland...
    neoplasm, LUNX expression in; human lung-specific gene, LUNX, a
    potential mol. marker for detection of micrometastasis in
    non-small-cell lung cancer
Lung, neoplasm...
    non-small-cell carcinoma, metastasis; human lung-specific gene, LUNX, a
    potential mol. marker for detection of micrometastasis in
    non-small-cell lung cancer
  CAS REGISTRY NUMBERS:
218438-77-8P amino acid sequence; human lung-specific gene, LUNX, a
    potential mol. marker for detection of micrometastasis in
    non-small-cell lung cancer
229162-20-3 261336-84-9 nucleotide sequence; human lung-specific gene,
    LUNX, a potential mol. marker for detection of micrometastasis in
    non-small-cell lung cancer
174068-42-9 244778-14-1 330693-00-0 330693-01-1 330693-02-2
    330693-03-3 330693-04-4 330693-05-5 unclaimed nucleotide sequence;
    human lung-specific gene, LUNX, a potential mol. marker for detection
    of micrometastasis in non-small-cell lung cancer
            (Item 3 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
             CA: 132(1)1796v
 132001796
                                 PATENT
 A novel method of diagnosing, monitoring, and staging colon cancer based
on colon-specific gene expression
  INVENTOR (AUTHOR): Macina, Roberto A.; Yang, Fei; Sun, Yongming
  LOCATION: USA
  ASSIGNEE: Diadexus Llc
  PATENT: PCT International ; WO 9960161 Al DATE: 19991125
  APPLICATION: WO 99US10498 (19990512) *US 86266 (19980521)
  PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;
G01N-033/53B; G01N-033/574B DESIGNATED COUNTRIES: CA; JP; US
  DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;
LU; MC; NL; PT; SE
  SECTION:
CA209002 Biochemical Methods
CA203XXX Biochemical Genetics
CA206XXX General Biochemistry
CA213XXX Mammalian Biochemistry
CA214XXX Mammalian Pathological Biochemistry
  IDENTIFIERS: colon cancer marker gene expression, diagnosis colon cancer
marker gene expression, sequence colon specific gene expression human
  DESCRIPTORS:
Gene, animal...
    Cln106; method of diagnosing, monitoring, and staging colon cancer
   based on colon-specific gene expression
Intestine... Intestine, neoplasm...
    colon; method of diagnosing, monitoring, and staging colon cancer based
    on colon-specific gene expression
Proteins, specific or class...
   CSG (colon-specific gene); method of diagnosing, monitoring, and
   staging lung cancer based on lung-specific gene expression
   enzyme-linked immunosorbent assay; method of diagnosing, monitoring,
   and staging colon cancer based on colon-specific gene expression
cDNA sequences...
    for colon-specific gene expression in human
Protein sequences...
    for colon-specific proteins in human
Immunoassay...
```

Proteins, specific or class...

immunoblotting; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression Immunoassay... immunohistochem.; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression Nucleic acid hybridization... in situ; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression Prognosis... method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression Diagnosis... mol.; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression Immunoassay... radioimmunoassay; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression PCR(polymerase chain reaction)... RT-PCR (reverse transcription-PCR); method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression Lung, neoplasm... squamous cell carcinoma; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression CAS REGISTRY NUMBERS: 251099-15-7 amino acid sequence; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression $251095 - \overline{5}8 - \overline{6}$ 251095 - 59 - 7 251095 - 60 - 0 251095 - 61 - 1 251095 - 62 - 2251095-63-3 251095-64-4 251099-13-5 251099-14-6 nucleotide sequence; method of diagnosing, monitoring, and staging colon cancer based on colon-specific gene expression (Item 4 from file: 399) DIALOG(R) File 399:CA SEARCH(R) (c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv. 132001795 CA: 132(1)1795u PATENT A novel method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression INVENTOR (AUTHOR): Yang, Fei; Macina, Roberto A.; Sun, Yongming LOCATION: USA ASSIGNEE: Diadexus Llc PATENT: PCT International; WO 9960160 A1 DATE: 19991125 APPLICATION: WO 99US10344 (19990512) *US 86212 (19980521) PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A; G01N-033/72B DESIGNATED COUNTRIES: CA; JP; US DESIGNATED REGIONAL: AT; BE ; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE SECTION: CA209002 Biochemical Methods CA203XXX Biochemical Genetics CA206XXX General Biochemistry CA213XXX Mammalian Biochemistry CA214XXX Mammalian Pathological Biochemistry IDENTIFIERS: lung cancer marker gene expression, diagnosis lung cancer marker gene expression, sequence lung specific gene expression human DESCRIPTORS: Lung, neoplasm... adenocarcinoma; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression enzyme-linked immunosorbent assay; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression cDNA sequences... for lung-specific gene expression in human Protein sequences...

immunoblotting; method of diagnosing, monitoring, and staging lung

for lung-specific proteins in human

cancer based on lung-specific gene expression

Immunoassay...

Immunoassay...

immunohistochem.; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Nucleic acid hybridization...

in situ; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Gene, animal...

Lng101 and Lng105 and Lng107; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Proteins, specific or class...

LSG (lung-specific gene); method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Lung, neoplasm...

metastasis; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Lung... Lung, neoplasm... Prognosis...

method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Diagnosis...

mol.; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Immunoassay...

radioimmunoassay; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

PCR(polymerase chain reaction)...

RT-PCR (reverse transcription-PCR); method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

Lung, neoplasm...

squamous cell carcinoma; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression CAS REGISTRY NUMBERS:

208065-42-3 251314-72-4 amino acid sequence; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression

208065-40-1 232268-26-7 251314-64-4 251314-65-5 251314-67-7 251314-68-8 251314-70-2 nucleotide sequence; method of diagnosing, monitoring, and staging lung cancer based on lung-specific gene expression